期刊文献+

肝细胞癌中OY-TES-1基因mRNA的表达 被引量:4

OY-TES-1 Gene mRNA Expression in Human Hepatocellular Carcinoma Tissues
下载PDF
导出
摘要 目的检测OY-TES-1基因mRNA在肝细胞癌(HCC)中的表达水平。方法建立实时定量PCR方法 ,检测56例HCC及37例配对癌旁组织中目的基因OY-TES-1及看家基因HPRT的表达,OY-TES-1 mRNA的表达量以OY-TES-1/HPRT表示,应用SPSS13.0统计分析软件进行数据分析。结果 (1)经实时定量PCR检测,HCC中OY-TES-1 mRNA阳性率为73.21%(41/56),癌旁组织阳性率为64.86%(24/37),有17对HCC及配对癌旁组织均表达阳性,OY-TES-1 mRNA在HCC及癌旁组织中的阳性表达率差异无统计学意义(P>0.05);(2)HCC中OY-TES-1 mRNA水平明显高于对应的癌旁组织(P<0.05),但与HCC患者的年龄、性别等临床资料无关。结论 OY-TES-1 mRNA在HCC中有较高的表达频率,其表达水平高于对应的癌旁组织,它有望作为用于HCC辅助诊断及免疫治疗的肿瘤抗原。OY-TES-1蛋白在HCC及癌旁组织中的表达及相关意义尚值得做进一步的研究。 Objective To investigate the expression level of OY-TES-1 mRNA in human hepatocellular carcinoma (HCC)tissues.Methods To establish quantitative real-time polymerase chain reaction for quantitative expression of OY-TES-1 mRNA.Fifty-six specimens of human HCC tissues and thirty-seven specimens of adjacent HCC tissues were analyzed for quantitative expression of target gene OY-TES-1 and housekeeping gene HPRT. OY-TES-1/HPRT was used to evaluate the expression level of OY-TES-1 mRNA.Data were dealt with statistical analysis software SPSS 13.0.Results (1) The expressive frequency of OY-TES-1 in HCC was 73.21%(41/56)while 64.86%(24/37)in adjacent HCC tissues by quantitative real-time PCR.Meanwhile,17 pairs show positive,which had no significant difference(P〉0.05).(2) The expression level of OY-TES-1 mRNA in human HCC tissues was higher than that in adjacent HCC tissues(P〈0.05).No relationship was found between the expression of OY-TES-1 genes and clinic pathological parameters (P〉0.05).Conclusion With higher expressive frequency and level in human HCC,OY-TES-1 is a potential target for antigen-specific immunotherapy and auxiliary diagnosis of HCC.Our interest will now focus on the expression of OY-TES-1 protein in HCC and its significance.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2010年第7期810-812,共3页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金资助项目(30360026 30760055)
关键词 癌-睾丸抗原 精子蛋白 肝细胞癌 定量PCR Cancer-testis antigen Sperm protein Hepatocellular carcinoma Quantitative PCR
  • 相关文献

参考文献13

  • 1Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data proeessing[J]. BMC Bioinformaties, 2005,6: 62[2005-03-21]. http: www. ncbi. nlrn. nih. gov/prac/artieles/PMC1274258/fool = pubmed.
  • 2范蓉,余良,肖绍文,何少健,罗彬,黄绍明,罗国容,谢小薰.精子蛋白sp32/OY-TES-1 mRNA及其蛋白在正常组织表达的探讨[J].解剖学报,2007,38(6):675-680. 被引量:7
  • 3Kim Y, Jeoung D. Role of CAGE, et al. A novel cancer/testis antigen, in various cellular processes, including tumorigene sis, cytolytie T lymphocyte induction, and cell motility[J]. J Mierobiol Biotechnol, 2008,18 (3) : 600 -610.
  • 4Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY- ESO-1 imminity: CD8 + T lymphocyte and antibody responses in peptide-vaccinated patients with NY ESO-1 + cancer[J]: Proc Natl Aead Sci USA,2000,97(22): 12198-12203.
  • 5王峰,范蓉,谢小薰.CT抗原—神经系统肿瘤免疫治疗的新靶向[J].肿瘤防治研究,2007,34(2):154-156. 被引量:2
  • 6Ono T, Kurashige T, Harada N, et al. Identification of proacrosin binding protein SP32 precursor as a human cancer/ testis antigen[J]. Proc Natl Acad Sci USA, 2001,98(6) :3282- 3287.
  • 7Baba T, Niida Y, Michikawa Y, et al. An acrosomal protein, SP32, in mammalian sperm is a binding protein specific for two proaerosins and an aerosin intermediate [ J ]. J Biol Chem, 1994,269(13) : 10133-10140.
  • 8Okumura H, Nagushi Y, Uanaha A, et al. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotox ic T-cell[J]. Microbiol Immunol,2005,49(11) :1009-1016.
  • 9范蓉,肖绍文,何少健,张小静,罗昱,罗国容,谢小薰.精子蛋白Sp32/OY-TES-1基因mRNA表达的探讨[J].解剖学报,2006,37(1):102-105. 被引量:8
  • 10Huggett J, Dheda K, Bustin S, et al. Real-time RT-PCR normalization: strategies and considerations[J]. Gene and Immunity,2005,6(4) : 279-284.

二级参考文献46

共引文献11

同被引文献34

  • 1Li Zhao, Dong-Cheng Mou, Zeng-An Wu, Ji-Run Peng, Lei Huang, Xi-Sheng Leng.Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients[J].World Journal of Gastroenterology,2010,16(32):4072-4078. 被引量:22
  • 2易石坚,钟德玝,杨竹林.金属硫蛋白在肝细胞癌中的表达及其临床意义[J].南华大学学报(医学版),2006,34(4):530-533. 被引量:4
  • 3Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in orarian cancer [J]. N Engl J Med, 2006, 364 (1): 34.
  • 4Ono T, Kurashige T, Harada N et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen [J]. Proc Natl AcadSci USA, 2001, 98 (6): 3282.
  • 5Tammela J, Ucnaka A, Ono T et al. OY - TES - 1 expression and serum immuoreactivity in epithelial ovarian cancer [J]. Int J Oncol, 2006, 29 (4): 903.
  • 6Filipowicz W, Jaskiewicz L, Kolb FA et al. Post - transcriptional gene silencing by siRNAs and miRNAs [J] . Curr Opin Struct Biol, 2005, 15 (3) : 331.
  • 7Campbell TN, Choy FY. RNA interference: past, present and future [J].Curr Issues Mol Biol, 2005, 7 (1): 1.
  • 8Almofti MR, Harashima H, Shinohara Y et al. Cationic liposome - mediated gene delivery: biophysical study and mechanism of internalization [J]. Arch Biochem Biophys, 2003, 410 (2): 246.
  • 9Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression [J]. Nat Rev Mol Cell Biol, 2003. 4 (6): 457.
  • 10江华,姜永强.肿瘤-睾丸抗原研究进展[J].军事医学科学院院刊,2007,31(4):387-390. 被引量:2

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部